Fuller & Thaler Asset Management’s United Therapeutics UTHR Stock Holding History

Fuller & Thaler Asset Management’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$120M	Sell	220,697 -59,708	-21%	-$33.6M	0.33%	106
2026 Q1	$166M	Sell	280,405 -10,208	-4%	-$5.08M	0.56%	44
2025 Q4	$142M	Sell	290,613 -24,692	-8%	-$11.5M	0.48%	66
2025 Q3	$132M	Sell	315,305 -71,741	-19%	-$24.1M	0.45%	81
2025 Q2	$111M	Sell	387,046 -104,081	-21%	-$31.1M	0.41%	86
2025 Q1	$151M	Sell	491,127 -41,787	-8%	-$14.3M	0.59%	47
2024 Q4	$188M	Sell	532,914 -35,478	-6%	-$13M	0.71%	32
2024 Q3	$204M	Sell	568,392 -6,584	-1%	-$2.22M	0.8%	29
2024 Q2	$183M	Buy	574,976 +1,901	+0.3%	+$503K	0.78%	25
2024 Q1	$132M	Buy	573,075 +141,959	+33%	+$32M	0.57%	52
2023 Q4	$94.8M	Buy	431,116 +216	+0.1%	+$49.8K	0.48%	72
2023 Q3	$97.3M	Sell	430,900 -1,520	-0.4%	-$350K	0.56%	63
2023 Q2	$95.5M	Sell	432,420 -91,174	-17%	-$20.2M	0.54%	65
2023 Q1	$117M	Sell	523,594 -4,573	-0.9%	-$1.13M	0.68%	48
2022 Q4	$147M	Sell	528,167 -23,241	-4%	-$5.87M	0.93%	21
2022 Q3	$115M	Sell	551,408 -102,005	-16%	-$22.8M	0.83%	29
2022 Q2	$154M	Sell	653,413 -10,882	-2%	-$2.21M	1.06%	17
2022 Q1	$119M	Sell	664,295 -67,095	-9%	-$12.8M	0.71%	36
2021 Q4	$158M	Buy	731,390 +29,292	+4%	+$5.75M	0.92%	26
2021 Q3	$130M	Buy	702,098 +77,919	+12%	+$15.3M	0.84%	30
2021 Q2	$112M	Buy	624,179 +17,386	+3%	+$3.31M	0.73%	40
2021 Q1	$101M	Buy	606,793 +515,942	+568%	+$86M	0.71%	43
2020 Q4	$13.8M	Buy	+90,851	New	+$11.9M	0.13%	163
2019 Q3	–	Sell	-128	Closed	-$10K	–	492
2019 Q2	$10K	Hold	128	–	–	﹤0.01%	457
2019 Q1	$15K	Hold	128	–	–	﹤0.01%	428
2018 Q4	$14K	Hold	128	–	–	﹤0.01%	434
2018 Q3	$16K	Buy	128 +3	+2%	+$371	﹤0.01%	417
2018 Q2	$14K	Hold	125	–	–	﹤0.01%	737
2018 Q1	$14K	Buy	+125	New	+$15.9K	﹤0.01%	732
2016 Q2	–	Sell	-35,300	Closed	-$3.93M	–	847
2016 Q1	$3.93M	Buy	35,300 +5,700	+19%	+$721K	0.08%	143
2015 Q4	$4.64M	Buy	29,600 +28,500	+2,591%	+$4.15M	0.1%	137
2015 Q3	$144K	Buy	1,100 +100	+10%	+$16K	﹤0.01%	430
2015 Q2	$174K	Sell	1,000 -200	-17%	-$36K	﹤0.01%	426
2015 Q1	$207K	Buy	1,200 +200	+20%	+$30.5K	0.01%	398
2014 Q4	$129K	Buy	1,000 +300	+43%	+$38.7K	﹤0.01%	451
2014 Q3	$90K	Sell	700 -200	-22%	-$20.6K	﹤0.01%	555
2014 Q2	$80K	Sell	900 -600	-40%	-$57.7K	﹤0.01%	615
2014 Q1	$141K	Buy	1,500 +600	+67%	+$61.4K	0.01%	526
2013 Q4	$102K	Hold	900	–	–	0.01%	521
2013 Q3	$71K	Buy	+900	New	+$65.8K	﹤0.01%	587

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

AssetMark Inc Concord, California $58.2B AUM 22.78% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Fuller & Thaler Asset Management's UTHR Position: Q2 2026 in Review

Fuller & Thaler Asset Management reduced its United Therapeutics (UTHR) stake by 21% in Q2 2026, selling an estimated $33.6M and leaving 220,697 shares worth $120M. The position accounts for 0.33% of the portfolio, ranked #106.

Fuller & Thaler Asset Management first reported a position in UTHR in Q3 2013 and has held it in 40 quarters since. The position peaked at $204M in Q3 2024. 647 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

Fuller & Thaler Asset Management held 220,697 shares of United Therapeutics worth $120M as of Q2 2026.
Fuller & Thaler Asset Management sold 59,708 United Therapeutics shares in Q2 2026, an estimated $33.6M.
United Therapeutics made up 0.33% of Fuller & Thaler Asset Management's portfolio in Q2 2026, its #106 holding.
Fuller & Thaler Asset Management first reported a position in United Therapeutics in Q3 2013 and has held it in 40 quarters since.
Fuller & Thaler Asset Management's United Therapeutics position peaked at $204M in Q3 2024.
647 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Fuller & Thaler Asset Management's 13F filing for Q2 2026, filed 12 Aug 2026.